Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
F01 in Autoimmune Diseases
NCT06208280Phase 1Recruiting
- Sponsor
- Renji Hospital
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SNC103 in systemic lupus erythematosus (SLE), granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA) and 4 more, sponsored by Renji Hospital. Primary endpoints: Proportion of subjects with Adverse Events (AEs) and Serious Adverse Events (SAEs) at 12 weeks and Proportion of subjects with Dose-Limiting Toxicity at 4 weeks. Started Jan 2024; status: recruiting.
02
Drugs
SNC103
03
Conditions
systemic lupus erythematosus (SLE)granulomatosis with polyangiitis (GPA)microscopic polyangiitis (MPA)dermatomyositis (DM)polymyositis (PM)
Beyond the preview
Go deeper on NCT06208280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06208280.